Oxford BioMedica plc is a UK‐based gene and cell therapy company specializing in the development and manufacture of advanced viral vector technologies. Founded as a spin-out from the University of Oxford in 1995, the company has grown into a global player in lentiviral vector research, production and commercial supply. Headquartered in Oxford, England, with a manufacturing facility in Segrate, Italy, Oxford BioMedica leverages its proprietary LentiVector® platform to advance treatments across a range of therapeutic areas.
The company’s core activities include the discovery, preclinical and clinical development of gene therapies, as well as contract development and manufacturing (CDMO) services for third-party biopharmaceutical partners. Its pipeline encompasses candidates targeting neurological disorders, oncology and ophthalmology, while its CDMO business supports high-profile collaborations such as the manufacturing of CAR-T cell therapies with Novartis and lentiviral vectors for vaccine candidates with global research organizations. Through these partnerships, Oxford BioMedica has demonstrated scalable, GMP-compliant production of clinical-grade vectors.
Over its history, Oxford BioMedica has built a robust intellectual property portfolio covering lentiviral vector design, vector production methods and gene delivery technologies. The company’s first vector was produced in the late 1990s, and since securing a London AIM listing in 2000, it has steadily expanded both its R&D footprint and manufacturing capacity. Today, its technologies serve clients and collaborators across Europe, North America and Asia, underpinning efforts to develop next-generation cell and gene therapies for rare and debilitating diseases.
Oxford BioMedica is led by CEO John Dawson, supported by an executive team with deep expertise in bioprocessing, regulatory affairs and clinical development. The board and management combine academic roots with commercial experience, guiding the company through strategic growth initiatives and the advancement of its proprietary pipeline. With a foundation in pioneering research and a focus on scalable manufacture, Oxford BioMedica continues to position itself at the forefront of the evolving gene therapy landscape.
AI Generated. May Contain Errors.
